^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ATG-034

    i
    Other names: ATG-034
    Associations

    News

    Trials
    Company:
    Antengene
    Drug class:
    ILT-3 antagonist
    Associations

    News

    Trials
    almost3years
    ATG-034, an LILRB4 antagonist antibody, reinvigorates dendritic cells and prevents tumor progression (AACR 2023)
    Our data show that ATG-034 reprograms tolDC, enhancing anti-tumor immunity, and demonstrates potent in vivo anti-tumor efficacy. Therefore, ATG-034 may be a promising strategy for the treatment of cancer.
    IO biomarker
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    CD20 expression • IL2RA expression • MRC1 expression
    |
    ATG-034